Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 20, 2026, 3:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–1 of 1 matching trial from the local directory fallback.

Local D1 index available.

Filters: Condition: T-cell/Histocyte-rich Large B-cell Lymphoma Clear all

Terminated Phase 1 Interventional Results available

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

NCT04933617

View directory record Official record

Conditions: Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB), High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma
Interventions: 18F-FDG - PET, Bone Marrow Aspiration, Bone Marrow Biopsy, CT Scan, Copanlisib, Cyclophosphamide, Doxorubicin, ECHO, EKG, Etoposide, Lumbar Puncture (LP), MRI Brain, Prednisone, Rituximab, Vincristine; Diagnostic Test · Procedure · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Jul 8, 2024 · Synced May 20, 2026, 3:12 AM EDT